Marker Therapeutics, Inc. (MRKR) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.12

From 52W high−45.21%

Volume573423.00

Market cap$20.01M

P/E (TTM)—

P/S (TTM)16.2x

Div yield—

Key dataOct 19, 2026

Open

$1.12

From 52W high

−45.21%

Volume

573423.00

Market cap

$20.01M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.0x

P/E (TTM)

—

RSI (14)

54.4

MomentumView details →

1D Return

+15.38%

YTD Return

−24.16%

SummaryUpdated Jun 1, 2026

Marker Therapeutics, Inc. (NASDAQ:MRKR) is a clinical-stage immuno-oncology company founded in 1999 and headquartered in Houston, Texas. The company went public in 2002 and focuses on developing innovative T cell-based immunotherapies and peptide-based vaccines for treating blood cancers and solid tumors. As a biotechnology firm in the clinical development phase, Marker Therapeutics operates without approved commercial products, instead advancing multiple experimental cancer treatments through various stages of human clinical trials.

Ask drillr about Marker Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.0x

EV/Sales

7.0x

P/S (TTM)

16.2x

P/B (TTM)

1.6x

ProfitabilityView details →

Gross Margin

−320.83%

Net Margin

−706.23%

EBITDA Margin

−707.46%

ROE (TTM)

−71.57%

ROA (TTM)

−59.70%

Asset Turnover

0.08x

GrowthView details →

Revenue YoY

−77.12%

EPS YoY

+64.96%

FCF YoY

+10.36%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+33.61%

EBITDA YoY

+7.36%

MomentumView details →

1D Return

+15.38%

YTD Return

−24.16%

1Y Return

+9.71%

RSI (14)

54.4

vs 50D SMA

−3.44%

vs 200D SMA

−19.65%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

6.03x

Quick Ratio

6.03x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.09

EPS Surprise

64.00%

Beats (12Q)

10/12

Next Q EPS Est

−$0.22

Avg Surprise (4Q)

59.19%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.23M

Net Income (TTM)

−8.71M

Op. CF (TTM)

−9.76M

Next earningsNov 12, 2026 →

Latest newsMore news →

The U.S. Food and Drug Administration awarded Marker Therapeutics a $2.6 million grant through its Orphan Products Clinical Trials grants program.16h ago

Marker Therapeutics filed its second-quarter 2026 10-Q with the SEC on August 14, 2026.60d ago

Similar companies

Quoin Pharmaceuticals, Ltd.QNRX VYNE Therapeutics Inc.VYNE BeyondSpring Inc.BYSI Sensei Biotherapeutics, Inc.SNSE OmniAb, Inc.OABIW Fractyl Health, Inc. Common StockGUTS Find similar companies →

Latest newsMore news →

The U.S. Food and Drug Administration awarded Marker Therapeutics a $2.6 million grant through its Orphan Products Clinical Trials grants program.16h ago Marker Therapeutics filed its second-quarter 2026 10-Q with the SEC on August 14, 2026.60d ago